Pharma channel feed

Many ques­tions, few an­swers in Sen­ate hear­ing on opaque US drug pric­ing sys­tem

8 years ago

Af­ter jump­ing ship at Eli Lil­ly, Politi­co re­ports Alex Azar may soon land top HHS job

8 years ago
People

Cas­cade of costs could push CAR-T ther­a­py to $1.5M per pa­tient

8 years ago

Al­ler­gan slammed as fed­er­al judge in­val­i­dates Resta­sis patents, slaps Mo­hawk deal

8 years ago

FDA gives No­vo Nordisk top grades for its di­a­betes drug semaglu­tide, but retinopa­thy re­mains key

8 years ago

EMA coun­ters the aca­d­e­mics who crit­i­cized the can­cer drug ap­proval process

8 years ago

Roche ties a $387M knot with Warp Dri­ve Bio in col­lab­o­ra­tion spot­light­ing new class­es of an­tibi­otics

8 years ago

FDA ex­perts give a thumbs-up to Aerie Phar­ma’s glau­co­ma drug

8 years ago

That $1.25B Bris­tol-My­ers IDO1 drug? In­cyte claims a for­mer staffer stole it

8 years ago
R&D

FDA ex­perts of­fer a unan­i­mous en­dorse­ment for Spark’s pi­o­neer­ing AAV gene ther­a­py for blind­ness

8 years ago
Cell/Gene Tx

Karyopharm bags a $193M Asian deal for se­linex­or and fol­lowup drug, shares jump

8 years ago

In a new set­back, FDA kicks back Acel­Rx’s ap­pli­ca­tion for pain med — shares tank again

8 years ago

J&J takes an­oth­er big step for­ward with next-gen prostate can­cer block­buster apa­lu­tamide

8 years ago

Bat­tered by mixed PhI­II da­ta, Treve­na ax­es R&D staff and hun­kers down around lead pain drug

8 years ago
R&D

The FDA's in­sid­er view on Aerie’s glau­co­ma drug: Yes on ef­fi­ca­cy, but…

8 years ago

Ten big lob­by­ing groups turn their guns on Al­ler­gan's con­tro­ver­sial patent gam­bit

8 years ago

With just a lit­tle en­cour­age­ment, biotech in­vestors are ready to fall in love again

8 years ago
People
R&D

Scott Got­tlieb likes his job run­ning the FDA, but he is­n't rul­ing out a big HHS pro­mo­tion

8 years ago

Gi­ant Mer­ck bud­dies up with lit­tle KalVista on lead drug, ig­nit­ing stock with a $760M deal

8 years ago

Ab­b­Vie jumps on the on­colyt­ics band­wag­on, em­brac­ing Turn­stone in new col­lab­o­ra­tion

8 years ago
R&D

Spark Ther­a­peu­tics faces a grilling as FDA pon­ders a pi­o­neer­ing OK for gene ther­a­py

8 years ago
Cell/Gene Tx

Biotech sci­en­tist/en­tre­pre­neur Saurabh Sa­ha makes an un­usu­al re­turn to the arms of a big — and ex­ces­sive­ly dis­creet — R&D group

8 years ago
People
R&D

Flex­ion nabs FDA OK for its po­ten­tial block­buster os­teoarthri­tis drug, trig­ger­ing new buy­out buzz

8 years ago

Fac­ing an ex­o­dus, EMA starts to line up temp re­place­ments as top staffers jump ship

8 years ago
First page Previous page 315316317318319320321 Next page Last page
A service from the Financial Times